Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study. (OPT-1)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03500068|
Recruitment Status : Recruiting
First Posted : April 17, 2018
Last Update Posted : April 23, 2018
|Condition or disease||Intervention/treatment||Phase|
|Carcinoma, Pancreatic Ductal||Diagnostic Test: biopsies & blood analyses||Not Applicable|
Rationale: Pancreatic adenocarcinoma is a malignancy with a poor prognosis. Resection is the only curative option and still 5-year survival rate is less than 10 percent. However, most patients present with advanced disease and are provided with palliative care. The nature of the tumour and the intense stromal reaction around the tumour cells leave pancreatic adenocarcinoma relatively insensitive to chemotherapeutics. Current models, such as cell lines or patient derived xenografts, cannot provide predictive information in a clinically relevant timeframe. Organoids and organotypic culture systems have emerged as promising new culturing techniques that maintain some of the complexity of the tumour. As most patients are ineligible for tumour resection, this project will focus on metastases and will generate organoids from that tissue. Using a combination of organoids and organotypic systems, treatment (non)response can be predicted, which may provide a personalized treatment setting for patients with advanced pancreatic adenocarcinoma.
Objective: To develop a model system and infrastructure to individualize the treatment of patients with advanced pancreatic adenocarcinoma. Additionally, we aim to identify predictors of therapy (non)response.
Study design: Observational laboratory studies (with DNA/RNA isolation, RNA sequencing, cell culturing, organoid culturing and xenografting) will be performed with tumour specimens. These organoids will be stored for future research.
Study population: All adult patients (> 18 years) with (a suspicion of) advanced pancreatic adenocarcinoma
Main study parameters/endpoints: The development of organoids from biopsies of metastases or primary tumour tissue of pancreatic cancer that correlate with clinical response. These models are then analysed for the expression of bio markers in organoid, organotypic and xenograft models. DNA/RNA profiles will be correlated to clinical and pathological characteristics such as therapy response, survival and TNM classification.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participating in this study requires a biopsy from the patient. The material will be obtained from the biopsy required for diagnosis or the patient is asked for consent for an additional tumor biopsy not required for diagnosis. The study could benefit patients as their organoids can be used to assess efficacy of first-line treatment and when necessary may provide an advice for second-line treatment options. Additionally, patients may benefit in the future, if biomarkers are found to predict therapy (non)response.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study|
|Actual Study Start Date :||September 4, 2017|
|Estimated Primary Completion Date :||September 1, 2019|
|Estimated Study Completion Date :||September 1, 2019|
- Diagnostic Test: biopsies & blood analyses
They will take blood and a biopsy from the metastase in the patient
- Developing organoids from advanced pancreatic cancer patients that predict non response or response [ Time Frame: 2 months ]
To assess whether there is a correlation between no response in patients and no response in organoids, a goodness of fit will be determined with Pearson's X2 test. Depending on the available data, the second scenario will be analysed similarly.
When organoids cannot be established from biopsy material, then this will be recorded and linked to clinical parameters.
- Functional studies will be done with the patient derived organoids to find biomarkers that correlate with response in organoids and patients. [ Time Frame: 2 months ]Similarly to our primary study parameter, the value of prediction for a biomarker will be assessed.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03500068
|Contact: M G van Mackelenberghfirstname.lastname@example.org|
|Contact: J W Wilmink, M.D. PhDemail@example.com|
|Academic Medical Center, Medical Oncology||Recruiting|
|Amsterdam, Netherlands, 1100 DD|
|Contact: J. W. Wilmink, MD, PhD, PhD 31 20 5665955 firstname.lastname@example.org|
|Contact: Lyda ter Hofstede 31 20 5668229 email@example.com|
|Principal Investigator: H. WM van Laarhoven, MD, PhD, PhD|
|Principal Investigator: J. W. Wilmink, M.D., Ph.D.|